Dulaglutide

Generic Name: Dulaglutide

Brand Names: Trulicity

Drug Type: Biotech

CAS Number: 923950-08-7

Unique Ingredient Identifier: WTT295HSY5

Background: Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular events. It is the first T2DM drug approved to reduce major adverse cardiovascular events (MACE) risk in primary and secondary prevention populations.

Indication: Dulaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years of age with type 2 diabetes mellitus. It is also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.

Associated Conditions: Major Adverse Cardiovascular Events, Type 2 Diabetes Mellitus

Clinical Trials

Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic Nephropathy

Not Applicable

Completed

Conditions: Type 2 Diabetic Nephropathy

Interventions: Drug: Dulaglutide Injection

First Posted Date: 2023-12-27

Last Posted Date: 2023-12-27

Lead Sponsor: The Affiliated Hospital of Xuzhou Medical University

Target Recruit Count: 300

Registration Number: NCT06182891

Locations: 🇨🇳
Department of Endocrinology, Xuzhou, Jiangsu, China

Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: HEC88473, Placebo, Dulaglutide

First Posted Date: 2023-11-28

Last Posted Date: 2025-04-29

Lead Sponsor: Dongguan HEC Biopharmaceutical R&D Co., Ltd.

Target Recruit Count: 234

Registration Number: NCT06148649

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳
Shijiazhuang People's Hospital, Shijiazhuang, Hebei, China

Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18)

Completed

Conditions: Liver Steatosis
Non-Alcoholic Fatty Liver Disease

Interventions: Drug: Control Rx
Drug: Empagliflozin
Drug: Dulaglutide

First Posted Date: 2023-07-14

Last Posted Date: 2023-07-14

Lead Sponsor: National and Kapodistrian University of Athens

Target Recruit Count: 78

Registration Number: NCT05946148

Locations: 🇬🇷
"Hippocration" General Hospital of Athens, Athens, Attiki, Greece

A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus
T2DM

Interventions: Drug: Ecnoglutide low dosage
Drug: Ecnoglutide high dosage
Drug: Dulaglutide
Drug: Metformin

First Posted Date: 2023-01-11

Last Posted Date: 2025-05-08

Lead Sponsor: Hangzhou Sciwind Biosciences Co., Ltd.

Target Recruit Count: 623

Registration Number: NCT05680129

Locations: 🇨🇳
ZHONGSHAN Hospital, Shanghai, Shanghai, China

A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Dulaglutide

First Posted Date: 2022-12-21

Last Posted Date: 2025-02-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 212

Registration Number: NCT05659537

Locations: 🇮🇳
Life Care Hospital and Research Centre, Bangalore, Karnataka, India
🇮🇳
Akshay Hospital, Pune, Maharashtra, India
🇮🇳
Virinchi Hospital, Hyderabad, Telangana, India

and more 4 locations

A Study of IBI362 in Participants With Type 2 Diabetes

Phase 3

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: IBI362
Drug: dulaglutide

First Posted Date: 2022-11-07

Last Posted Date: 2024-08-23

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 731

Registration Number: NCT05606913

Locations: 🇨🇳
China-Japan Friendship Hospital, Beijing, Beijin, China

A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)

Phase 4

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Dulaglutide
Drug: Tirzepatide

First Posted Date: 2022-10-03

Last Posted Date: 2024-08-16

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 282

Registration Number: NCT05564039

Locations: 🇺🇸
Juno Research, Houston, Texas, United States
🇺🇸
Biopharma Informatic, LLC, Houston, Texas, United States
🇷🇴
Diabdana, Oradea, Bihor, Romania

and more 33 locations